Evidence map›Paper›PMID 38832317›Full record

ArticleFrontiers in cardiovascular medicine2024

Sodium-glucose cotransporter-2 inhibitors improve cardiovascular outcomes post-acute coronary syndrome complicated by acute heart failure.

Alaa Rahhal, Tahseen Hamamyh, Ammar Chapra, Khaled J Zaza, Mostafa Najim, Mohammad Hemadneh, Hazem Faraj, Wael Kanjo, Ahmed Yasin, Haneen Toba and 10 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Alaa RahhalPharmacy Department, Hamad Medical Corporation, Doha, Qatar.
Tahseen HamamyhCardiology Department, Hamad Medical Corporation, Doha, Qatar.
Ammar ChapraCardiology Department, Hamad Medical Corporation, Doha, Qatar.
Khaled J ZazaAnesthesiology, Intensive Care and Perioperative Medicine Department, Hamad Medical Corporation, Doha, Qatar.
Mostafa NajimInternal Medicine Department, Rochester Regional Health, New York, NY, United States.
Mohammad HemadnehInternal Medicine Department, Hamad Medical Corporation, Doha, Qatar.
Hazem FarajInternal Medicine Department, Hamad Medical Corporation, Doha, Qatar.
Wael KanjoInternal Medicine Department, Hamad Medical Corporation, Doha, Qatar.
Ahmed YasinInternal Medicine Department, Hamad Medical Corporation, Doha, Qatar.
Haneen TobaInternal Medicine Department, Hamad Medical Corporation, Doha, Qatar.
Wafa MohammedInternal Medicine Department, Hamad Medical Corporation, Doha, Qatar.
Mohammad Khair HamadEndocrinology Department, Hamad Medical Corporation, Doha, Qatar.
Nawras Al-TikretyInternal Medicine Department, Hamad Medical Corporation, Doha, Qatar.
Mhd Baraa HabibCardiology Department, Hamad Medical Corporation, Doha, Qatar.
Ahmed AwaisuDepartment of Clinical Pharmacy and Practice, Qatar University, Doha, Qatar.
Ahmed MahfouzPharmacy Department, Hamad Medical Corporation, Doha, Qatar.
Sumaya AlyafeiPharmacy Department, Hamad Medical Corporation, Doha, Qatar.
Abdul Rahman ArabiInterventional Cardiology Department, Hamad Medical Corporation, Doha, Qatar.
Ashfaq PatelHeart Failure Department, Hamad Medical Corporation, Doha, Qatar.
Mohammed Al-HijjiInterventional Cardiology Department, Hamad Medical Corporation, Doha, Qatar.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Acute coronary syndrome (ACS) remains a risk factor for heart failure (HF). Therefore, we aimed to assess the cardioprotective role of sodium-glucose cotransporter-2 (SGLT2) inhibitors post-ACS in patients with acute HF (AHF) and diabetes. Methods: We conducted a retrospective observational cohort study employing propensity score matching. This study involved patients with diabetes admitted with ACS complicated by AHF, defined as either new clinical HF requiring diuretics during the index admission or having an ejection fraction (EF) of <40%. The study population was divided into two groups; (1) SGLT2 inhibitor users and (2) SGLT2 inhibitor non-users. The Cox proportional hazard regression analysis was used to evaluate the outcomes. Results: A total of 465 patients (93% male; mean age, 55 ± 10 years) were included in this study. Using a 1 : 1 propensity score matching, 78 patients were included per arm with an absolute standardized difference of <0.1 for all baseline characteristics. The use of SGLT2 inhibitors resulted in lower composite outcomes of ACS, HF hospitalization, and all-cause mortality at 1 month and 12 months [1 month: 2.6% vs. 11.5%, HR = 0.20 (0.04-0.94), Conclusion: The findings suggest that SGLT2 inhibitors may confer cardioprotective effects in ACS-induced AHF, thereby widening the spectrum for indications of SGLT2 inhibitors.

Indexed as

acute coronary syndromecardioprotectionheart failureHF hospitalizationsodium–glucose cotransporter-2 (SGLT-2) inhibitors

Identifiers

PMID38832317
PMCPMC11144919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.